This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases an updated global demand analysis for seasonal influenza vaccines.
VacZine Analytics Ltd (Assay Advantage)
VacZine Analytics is an established strategic research publisher based in the United Kingdom.
Telephone: +44 (0)1279 927 049
Address :
Carlton House Bells Hill Bishops Stortford
Post Code: CM23 2NN
Country: United Kingdom
Website: http://www.vaczine-analytics.com
Membership Type: Professional Individual and Corporate <5
VacZine Analytics is a strategic research publisher based in the United Kingdom since 2007. Its aim is to provide high-quality disease and commercial analysis to those within or wishing to enter the vaccines business. Its key focus is to help clients build the case for developing new vaccines. VacZine Analytics has now published >75 analyses focused on vaccine preventable (or modifiable) diseases/conditions. We believe our portfolio is the largest and most vaccine focused available globally. Our clients are the top vaccine manufacturers, biotech/mid-tier space and academic/not-for-profit institutions.
There are no Products & Services to display
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases an updated global demand analysis for norovirus vaccines.
05-06-2020
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new global demand analysis for novel coronavirus [COVID-19] vaccines.
15-04-2020
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of Chikungunya vaccines. Relative to other healthcare priorities in affected countries, is a Chikungunya vaccine high on the list?
12-02-2020
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of norovirus vaccines.
03-10-2019
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of Porphyromonas gingivalis vaccines.
13-09-2019
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand-new commercial assessment of Lyme Borreliosis (Lyme Disease) vaccines.
17-06-2019
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines and infectious diseases, releases a brand new commercial assessment of anti-Respiratory Syncytial Virus (RSV) monoclonal antibodies. If used in all, rather than selected infants, this product concept promises a new alternative to vaccines for tackling this dangerous pathogen. But does more...
11-04-2019
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines, releases a brand new commercial assessment of Respiratory Syncytial Virus (RSV) vaccines. The field is one of the most active in the vaccine industry with many competitors investigating numerous approaches. But will the first mover reap the biggest reward?
26-02-2019
This month VacZine Analytics, a UK-based strategic research publisher exclusively focused on vaccines, releases three detailed demand analyses for MERS-CoV, Lassa virus and Nipah virus vaccines.
22-01-2019
This month VacZine Analytics releases an updated analysis focused on the high-profile emerging field of mRNA vaccines. This technology promises much, and analysis shows the pipeline is gathering momentum.
16-01-2019
This month VacZine Analytics releases MarketVIEW: Lassa fever vaccines. Lassa Fever is a priority target for international stakeholders, with significant sums of money already donated to develop a preventative vaccine. After apparent success with Ebola vaccine development, should the wider industry be interested in this new business model?
03-07-2018
This month VacZine Analytics releases MarketVIEW: Chikungunya vaccines. As more countries report local or autochthonous transmission of this problematic virus, and two vaccines receive priority designation, VacZine Analytics investigates commercial potential.
19-06-2018
This month VacZine Analytics releases its newly updated value/volume forecast for the global market for seasonal influenza vaccines. The influenza vaccine recommendations for 35 countries (13 Western and 21 Emerging/ROW) have been assessed, with some interesting findings.
05-06-2018
This month VacZine Analytics releases a new commercial analysis focused on Human Papilloma Virus (HPV) therapeutic vaccines. With efficacy signals observed in cervical neoplasias and established cancers, this approach may reinvigorate the concept of a "cancer" vaccine.
29-03-2018
This month VacZine Analytics releases a brand new analysis focused on the high profile emerging field of mRNA vaccines. This technology promises much, but what is real and what is hype?
21-03-2018
This month VacZine Analytics has updated both its dengue (endemic) and dengue (travelers) vaccine forecasts giving its latest view on this controversial vaccine market.
08-02-2018
A brand-new research study: "MarketVIEW: Opioid use disorder (OUD) vaccines report” has recently been added to VacZine Analytics portfolio offering.
01-02-2018
What is the most financially viable vaccine strategy for Chagas disease vaccines? Today UK based vaccine strategic consultancy releases a brand new market analysis MarketVIEW: Chagas disease vaccines.
19-11-2013
Who will benefit from the boom in inactivated polio virus vaccines? Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for inactivated polio virus vaccines.
28-10-2013
Pages
There are no events to display
There are no jobs to display
No Blog articles found
